Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

PURPOSE: To evaluate the safety and efficacy of panobinostat plus everolimus in patients with relapsed Hodgkin and non-Hodgkin lymphoma. The concept was supported by the single agent clinical activity of histone deacetylase inhibitors and mTOR inhibitors, and on the in vitro mechanism-based synergis...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Oki, Yasuhiro, Buglio, Daniela, Fanale, Michelle, Fayad, Luis, Copeland, Amanda, Romaguera, Jorge, Kwak, Larry W., Pro, Barbara, de Castro Faria, Silvana, Neelapu, Sattva, Fowler, Nathan, Hagemeister, Fredrick, Zhang, Jiexin, Zhou, Shouhao, Feng, Lei, Younes, Anas
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4409814/
https://ncbi.nlm.nih.gov/pubmed/24097867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1906
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires